Profile data is unavailable for this security.
About the company
Mithra Pharmaceuticals SA is a Belgian-based company active in the pharmaceutical industry. The Company is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The Company provides three development candidates built on Mithra’s estrogen platform, Estetrol (E4): Estelle, a solution for oral contraception, PeriNesta, the oral treatment targeting perimenopause and Donesta, a hormone therapy. The Company also develops and manufactures therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. The Company operates in more than 100 countries around the world and is headquartered in Liege, Belgium.
- Revenue in EUR (TTM)40.16m
- Net income in EUR-173.50m
- Incorporated1999
- Employees229.00
- LocationMithra Pharmaceuticals SARue de l'Expansion 57FLEMALLE 4400BelgiumBEL
- Phone+32 43533700
- Fax+32 43492821
- Websitehttps://www.mithracdmo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arterra Bioscience SpA | 3.30m | 1.08m | 12.98m | 30.00 | 12.01 | 1.20 | 7.65 | 3.93 | 0.1624 | 0.1624 | 0.4985 | 1.62 | 0.263 | 1.18 | -- | -- | 8.57 | 10.57 | 9.44 | 12.30 | 55.03 | 60.57 | 32.57 | 34.31 | 7.47 | -- | -- | -- | -7.28 | 6.36 | -23.89 | 0.6056 | -- | -- |
| Pila Pharma AB | 130.06k | -882.74k | 13.28m | 1.00 | -- | 22.43 | -- | 102.13 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| NicOx SA | 3.57m | -17.36m | 13.35m | 11.00 | -- | 0.2909 | -- | 3.74 | -0.3721 | -0.3721 | 0.0753 | 0.9128 | 0.0394 | -- | 1.83 | 324,909.10 | -19.13 | -19.22 | -21.35 | -20.78 | -- | -- | -485.70 | -370.14 | -- | -- | 0.3172 | -- | -54.78 | 7.25 | 36.57 | -- | -13.35 | -- |
| Xintela AB | 33.51k | -4.38m | 13.61m | -- | -- | -- | -- | 406.08 | -0.1217 | -0.1217 | 0.0008 | -0.0136 | 0.0193 | -- | 0.0447 | -- | -252.59 | -181.06 | -- | -391.61 | 100.00 | -- | -13,061.54 | -235,894.00 | -- | -49.47 | -- | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| Lipidor AB | 7.73k | -1.03m | 13.73m | -- | -- | -- | -- | 1,775.25 | -0.1049 | -0.1049 | 0.0008 | -0.0817 | 0.0122 | -- | 0.19 | -- | -162.65 | -59.41 | -- | -75.10 | -- | -- | -13,322.99 | -643.36 | -- | -- | -- | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| Synairgen plc | 0.00 | -11.84m | 13.82m | 30.00 | -- | 0.7304 | -- | -- | -0.0496 | -0.0496 | 0.00 | 0.0793 | 0.00 | -- | -- | 0.00 | -41.40 | -54.75 | -48.86 | -60.72 | -- | -- | -- | -83,247.62 | -- | -- | 0.00 | -- | -- | -- | 63.74 | -- | 0.00 | -- |
| Vo2 Cap Holding AB (publ) | 30.47m | 285.71k | 14.12m | 103.00 | 48.96 | 0.7183 | 3.11 | 0.4633 | 0.0607 | 0.0607 | 6.50 | 4.13 | 0.7493 | -- | 7.03 | 3,328,282.00 | 0.7023 | -0.2564 | 0.9347 | -0.3839 | 34.62 | 23.36 | 0.9373 | -0.2409 | -- | 1.18 | 0.1564 | -- | -26.09 | 85.65 | -57.92 | -- | -17.96 | -- |
| Mithra Pharmaceuticals SA | 40.16m | -173.50m | 14.45m | 229.00 | -- | -- | -- | 0.3599 | -2.51 | -2.51 | 0.6363 | -1.49 | 0.1102 | 0.4452 | 0.777 | -- | -47.60 | -22.24 | -70.17 | -27.69 | 45.34 | 73.13 | -432.08 | -199.11 | 0.4339 | -3.07 | 2.01 | -- | -40.06 | -7.05 | -191.01 | -- | -- | -- |
| Vivesto AB | 0.00 | -10.38m | 14.61m | 6.00 | -- | 0.868 | -- | -- | -0.219 | -0.219 | 0.00 | 0.352 | 0.00 | -- | -- | 0.00 | -44.08 | -- | -47.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | 64.80 | -- | -- | -- |
| Proteome Sciences plc | 5.96m | -2.90m | 14.73m | 35.00 | -- | -- | -- | 2.47 | -0.0083 | -0.0083 | 0.017 | -0.0104 | 0.4209 | 3.89 | 3.04 | 143,657.10 | -20.45 | -1.22 | -- | -- | 32.76 | 54.53 | -48.59 | -2.20 | 0.2667 | -2.03 | 1.29 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
| Genincode PLC | 2.56m | -8.32m | 14.95m | 36.00 | -- | 5.30 | -- | 5.84 | -0.0732 | -0.0732 | 0.0225 | 0.0135 | 0.2703 | 21.88 | 3.33 | 60,000.00 | -87.79 | -- | -124.10 | -- | 47.31 | -- | -324.81 | -- | 1.24 | -- | 0.1883 | -- | 51.05 | -- | -26.21 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -3.50m | 15.09m | 5.00 | -- | -- | -- | -- | -4.44 | -4.44 | 0.00 | -0.49 | 0.00 | -- | -- | 0.00 | -247.63 | -127.85 | -402.13 | -184.50 | -- | -- | -- | -293,228.70 | -- | -- | -- | -- | -- | -- | 2.38 | -- | -- | -- |
| Ikonisys SA | 538.56k | -2.40m | 15.19m | 11.00 | -- | 0.8235 | -- | 28.21 | -0.2499 | -0.2499 | 0.056 | 1.75 | 0.0246 | 1.14 | 6.20 | 48,960.00 | -10.94 | -- | -12.55 | -- | 2.72 | -- | -444.76 | -- | 0.0818 | -36.79 | 0.1007 | -- | 68.94 | -- | -328.57 | -- | -- | -- |
| BioMaxima SA | 11.11m | 82.42k | 15.46m | 115.00 | 185.91 | 1.44 | 21.71 | 1.39 | 0.0869 | 0.0869 | 11.68 | 11.22 | 0.6653 | 1.88 | 4.77 | 423,217.40 | 0.4935 | 16.44 | 0.5661 | 22.44 | 48.78 | 40.72 | 0.7417 | 12.84 | 1.06 | 0.9304 | 0.214 | -- | -67.22 | 9.13 | -97.97 | -- | 0.7404 | -- |
| Plant Advanced Technologies PAT SA | 1.68m | 79.16k | 15.53m | 56.00 | 193.24 | 1.81 | 26.78 | 9.23 | 0.0725 | 0.0725 | 1.54 | 7.73 | 0.1118 | -0.4123 | 1.60 | -- | 0.5262 | -3.53 | 0.6534 | -4.39 | 128.03 | 134.21 | 4.71 | -33.16 | 0.4183 | -15.32 | 0.3402 | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Mithra Pharmaceuticals SA's reporting currency: Euro EUR
0.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BNP Paribas Asset Management Belgium SAas of 31 May 2024 | 359.75k | 0.52% |
| BNP Paribas Asset Management Europe SASas of 29 Nov 2023 | 111.92k | 0.16% |
| State of Wisconsin Investment Boardas of 31 Dec 2022 | 4.88k | 0.01% |
| BlackRock Investment Management (UK) Ltd.as of 31 Jul 2023 | 2.47k | 0.00% |
| SSgA Funds Management, Inc.as of 05 Jun 2024 | 516.00 | 0.00% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 419.00 | 0.00% |
| Credit Suisse Asset Management (Schweiz) AGas of 30 Jun 2023 | 0.00 | 0.00% |
| AXA Investment Managers (Paris) SAas of 31 Oct 2023 | 0.00 | 0.00% |
| CAPFI DELEN Asset Management NVas of 31 Mar 2023 | 0.00 | 0.00% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 13 Jun 2024Source: FactSet Research Systems Inc.
